Prognostic Impact of Claudin18.2 and TROP2 Expression in Advanced Gastric Cancer Treated With Nivolumab
Anticancer Research · 2026
DOI: 10.21873/anticanres.18006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2026. Verfasst von Takahito Awatsu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Stomach Neoplasms, Cell Adhesion Molecules, Antigens, Neoplasm, Claudins. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
- Department of Gastroenterology, Juntendo University Faculty of Medicine, Tokyo, Japan.
- Cancer Chemotherapy Center, Osaka Medical and Pharmaceutical University, Osaka, Japan.
- Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan; hshouji@ncc.go.jp.
- Department of Pathophysiological Research and Therapeutics for Gastrointestinal Disease, Juntendo University Faculty of Medicine, Tokyo, Japan.
Zitieren
APA
Awatsu, T., Kadono, T., Shoji, H., Hirose, T., Hirano, H., Okita, N., Takashima, A., Nagahara, A., & Kato, K. (2026). Prognostic Impact of Claudin18.2 and TROP2 Expression in Advanced Gastric Cancer Treated With Nivolumab. Anticancer Research. https://doi.org/10.21873/anticanres.18006
Vancouver
Awatsu T, Kadono T, Shoji H, Hirose T, Hirano H, Okita N, et al. Prognostic Impact of Claudin18.2 and TROP2 Expression in Advanced Gastric Cancer Treated With Nivolumab. Anticancer Research. 2026. doi:10.21873/anticanres.18006
BibTeX
@article{Awatsu2026,
author = {Awatsu, Takahito and Kadono, Toru and Shoji, Hirokazu and Hirose, Toshiharu and Hirano, Hidekazu and Okita, Natsuko and Takashima, Atsuo and Nagahara, Akihito and Kato, Ken},
title = {Prognostic Impact of Claudin18.2 and TROP2 Expression in Advanced Gastric Cancer Treated With Nivolumab},
journal = {Anticancer Research},
year = {2026},
doi = {10.21873/anticanres.18006}
}
EUVIMED